Document Detail


Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.
MedLine Citation:
PMID:  15660234     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We aimed to compare and evaluate the efficacies of a continuous regimen of intranasal salmon calcitonin (SCT) and two cyclic regimens (different cyclic regimens from previous studies) based on alternating 15 days or on 10 days consecutively per month for 1 year in the treatment of postmenopausal osteoporosis. We performed an open-label, prospective, randomized clinical trial. A total of 120 postmenopausal osteoporotic participants between 50 and 65 years old were randomly assigned to one of three treatment groups. Patients in group 1 (n = 40) received continuously SCT nasal spray at a dose of 200 IU/day, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1-alpha hydroxyvitamin D3, for 1 year. Patients in group 2 (n = 40) received cyclically SCT nasal spray at a dose of 200 IU/day on alternating 15 days per month, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1-alpha hydroxyvitamin D3, for 1 year. Patients in group 3 (n = 40) received cyclically SCT nasal spray on 10 days consecutively per month (20 days/month rest), plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1-alpha hydroxyvitamin D3, for 1 year. Data was evaluated by repeated analysis of variance (ANOVA). In addition, statistical differences between groups were assessed by the two-tailed Student's t test. After 1 year of the study, seven patients from group 1, eight patients from group 2 and five patients from group 3 withdrew from the study. No patient discontinued the study because of adverse drug effects. There was a statistically-significant improvement in pain intensity VAS scores at the end of the year to baseline scores in all three groups (p < 0.001). There was no significant difference in pain intensity VAS scores between groups at the end of the year (p > 0.05). Lumbar and femur neck BMD scores improved significantly at the end of treatment in all three groups (p < 0.05). There was no statistically-significant difference in BMD scores between groups at final (p > 0.05). Urinary DPD/Cre levels decreased significantly in all three groups by the end of the year (p < 0.05). There was no statistically-significant difference in urinary DPD/Cre final levels between groups (p > 0.05). According to the results of the present study, consecutive 10 days therapy with SCT, which is the first in the literature to our knowledge, is as effective as the other two regimens in the treatment of osteoporosis. Both cyclic regimens in our study (alternating 15 days and 10 consecutive days each month for 1 year) do appear to offer some advantages, especially economically and clinically, as compared to continuous treatment.
Authors:
I Tekeo?lu; B Adak; M Budancamanak; A Demirel; L Ediz
Related Documents :
12054164 - The effects of growth hormone replacement therapy on bone metabolism in adult-onset gro...
8501744 - Metabolic bone status in young women with juvenile chronic arthritis.
20635084 - Hypoparathyroidism after total parathyroidectomy plus subcutaneous autotransplantation ...
3921684 - Influence of preoperative parenteral alimentation on postoperative growth in adolescent...
25438284 - Endoscopic band ligation and esophageal stents for acute variceal bleeding.
920124 - Below-knee amputation for ischaemic gangrene. prospective, randomized comparison of a t...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial     Date:  2005-01-20
Journal Detail:
Title:  Rheumatology international     Volume:  26     ISSN:  0172-8172     ISO Abbreviation:  Rheumatol. Int.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-12-12     Completed Date:  2006-09-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  157-61     Citation Subset:  IM    
Affiliation:
Y?z?nc? Yil University PMR and Rheumatology, Van, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Administration, Intranasal
Aged
Bone Density / drug effects
Bone Density Conservation Agents / therapeutic use*
Bone and Bones / drug effects,  metabolism,  radiography
Calcitonin / administration & dosage,  therapeutic use*
Calcium / therapeutic use
Cholecalciferol / administration & dosage,  analogs & derivatives
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Middle Aged
Osteoporosis, Postmenopausal / drug therapy*,  metabolism,  physiopathology
Pain / drug therapy,  physiopathology,  prevention & control
Chemical
Reg. No./Substance:
0/1-hydroxy-24-oxovitamin D3; 0/Bone Density Conservation Agents; 67-97-0/Cholecalciferol; 7440-70-2/Calcium; 9007-12-9/Calcitonin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development of multiple malignancies after immunosuppression in a patient with Wegener's granulomato...
Next Document:  The -590 IL-4 promoter polymorphism in patients with rheumatoid arthritis.